A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection
- 1 August 2014
- journal article
- research article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 21 (4), 615-628
- https://doi.org/10.1530/erc-14-0190
Abstract
A critical requirement in neuroendocrine tumor (NET) management is a sensitive, specific and reproducible blood biomarker test. We evaluated a PCR-based 51 transcript signature (NETest) and compared it to chromogranin A (CgA), pancreastatin (PST) and neurokinin A (NKA). The multigene signature was evaluated in two groups: i) a validation set of 40 NETs and controls and ii) a prospectively collected group of NETs (n=41, 61% small intestinal, 50% metastatic, 44% currently treated and 41 age-sex matched controls). Samples were analyzed by a two-step PCR (51 marker genes) protocol and ELISAs for CgA, PST and NKA. Sensitivity comparisons includedχ2, non-parametric measurements, ROC curves and predictive feature importance (PFAI) analyses. NETest identified 38 of 41 NETs. Performance metrics were: sensitivity 92.8%, specificity 92.8%, positive predictive value 92.8% and negative predictive value 92.8%. Single analyte ELISA metrics were: CgA 76, 59, 65, and 71%; PST 63, 56, 59, and 61% and NKA 39, 93, 84, and 60%. The AUCs (ROC analysis) were: NETest: 0.96±0.025, CgA: 0.67±0.06, PST 0.56±0.06, NKA: 0.66±0.06. NETest significantly outperformed single analyte tests (area differences: 0.284–0.403,Z-statistic 4.85–5.9,P95% sensitivity and specificity, AUC =0.98 vs single analytes: 59–67% sensitivity, AUCs: 0.58–0.63). The NETest is significantly more sensitive and efficient (>93%) than single analyte assays (CgA, PST or NKA) in NET diagnosis. Blood-based multigene analytic measurement will facilitate early detection of disease recurrence and can predict therapeutic efficacy.Keywords
This publication has 61 references indexed in Scilit:
- Theranostic and Molecular Classification of Breast CancerArchives of Pathology & Laboratory Medicine, 2014
- Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumorsEuropean Journal of Radiology, 2013
- The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional StudyPLOS ONE, 2013
- Evaluation of a Multiplex Assay for Estimation of HIV-1 IncidencePLOS ONE, 2013
- The Evolving Landscape of Neuroendocrine TumorsSeminars in Oncology, 2013
- Characterization of a multiplex, 12-biomarker test for rheumatoid arthritisJournal of Pharmaceutical and Biomedical Analysis, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Serum peptide profiles in patients with carcinoid tumorsThe American Journal of Surgery, 2003
- Pancreastatin Plasma Levels in Patients with Primary HyperparathyroidismWorld Journal of Surgery, 2000
- Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin γ) on the expression of male rat sexual behaviorPhysiology & Behavior, 1993